Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is stage IV. Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.
PRIMARY OBJECTIVE:
I. To identify multiple distinct diagnostic subtypes within the syndrome of CC as defined by host characteristics (e.g. cachexia symptoms, physical activity, physical function, blood biomarkers including hemoglobin and albumin, and body composition) at baseline and change in these factors over time in patients with cancer at high risk for CC.
SECONDARY OBJECTIVES:
I. To determine the association of each CC phenotype with overall survival. II. To validate CC diagnostic phenotypes developed in a separate, independent cachexia observational study performed by our collaborators at Kaiser Permanente.
III. To collect human samples of blood, tumor tissue, and medical images and build a large, comprehensive CC database clinically annotated with cancer-related outcomes, cachexia symptoms, and physical function data.
EXPLORATORY OBJECTIVE:
I. To evaluate for tumor-derived factors contributing to CC by determining the association between interleukin-6 (IL-6) expression in tumor and IL-6 and CC chemokine ligand 2 (CCL2) levels in the blood in patients with CC.
OUTLINE: This is an observational study.
Patients complete surveys over 30 minutes, undergo physical function tests over 30 minutes, undergo collection of blood and archived tumor samples, and wear actigraph over 24 hours for 7 days to record daily sleep and exercise activity at baseline and 3-month follow-up. Additionally, patients undergo standard of care computed tomography (CT) or positron emission tomography (PET)/CT scans throughout the study and patients' medical records are also reviewed at baseline, 3-month and 1-year follow-up.
Inclusion Criteria:
Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer
Plan to start first-line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, interventional clinical trial) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Be able to understand, speak and read English
Be 18 years of age or older
Exclusion Criteria:
Fort Smith, Arkansas 72903, United States
800-378-9373
Centennial, Colorado 80112, United States
Englewood, Colorado 80113, United States
Englewood, Colorado 80113, United States
Littleton, Colorado 80120, United States
Lone Tree, Colorado 80124, United States
Wilmington, Delaware 19801, United States
Washington D.C., District of Columbia 20007, United States
Savannah, Georgia 31405, United States
Grand Rapids, Michigan 49503, United States
Maple Grove, Minnesota 55369, United States
Henderson, Nevada 89074, United States
Las Vegas, Nevada 89144, United States
Las Vegas, Nevada 89169, United States
Rochester, New York 14606, United States
Wilkes-Barre, Pennsylvania 18711, United States
Hilton Head Island, South Carolina 29926-3827, United States
Brookfield, Wisconsin 53045, United States
Green Bay, Wisconsin 54303, United States
Milwaukee, Wisconsin 53211, United States
Stevens Point, Wisconsin 54482, United States
Sturgeon Bay, Wisconsin 54235-1495, United States
Summit, Wisconsin 53066, United States
ncorp@aurora.org414-302-2304
Wauwatosa, Wisconsin 53226, United States
research@beebehealthcare.org302-291-6730
lbarone@christianacare.org302-623-4450
lbarone@christianacare.org302-623-4450
lbarone@christianacare.org302-623-4450
research@beebehealthcare.org302-291-6730
lbarone@christianacare.org302-623-4450
202-444-2223
ClinicalTrials@northside.com404-303-3355
cancerpatient.navigator@nghs.com770-219-8800
cdean@iacthealth.com706-478-7968
Clinical.trials@northside.com404-303-3355
cancerpatient.navigator@nghs.com770-219-8800
770-219-9010
Clinical.trials@northside.com404-303-3355
Lorraine.OHara@hcahealthcare.com912-350-7887
underberga@sjchs.org912-819-5704
800-648-1935
maryann.heddon@sgmc.org229-259-4628
i.webster@hawaiicancercare.com808-524-6115
808-532-0315
808-545-8548
808-522-4333
808-531-8521
808-983-6090
info@hawaiicancercare.com808-539-2273
808-486-6000
808-487-7447
rohta@queens.org
618-463-5623
847-842-4847
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
clinical.research@sih.net618-457-5200
clinical.research@sih.net618-985-3333
andersonj@illinoiscancercare.com309-243-3605
morganthaler.jodi@mhsil.com217-876-4762
773-296-5360
advocateresearch@advocate.com630-929-6129
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
815-285-7800
Barbara.barhamand@advocatehealth.com630-275-1270
morganthaler.jodi@mhsil.com217-876-4762
847-429-2907
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
708-799-9995
andersonj@illinoiscancercare.com309-243-3605
advocateresearch@advocatehealth.com630-929-6129
advocateresearch@advocatehealth.com630-929-6129
andersonj@illinoiscancercare.com309-243-3605
Research@Carle.com800-446-5532
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
800-323-8622
ncorp@aah.org
andersonj@illinoiscancercare.com309-243-3605
847-384-3621
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
815-664-4141
andersonj@illinoiscancercare.com309-243-3605
217-545-7929
800-444-7541
pallante.beth@mhsil.com217-528-7541
Research@carle.com800-446-5532
andersonj@illinoiscancercare.com309-243-3605
Elisemarie.curry@ochsner.org504-842-8084
frank.crum@christianacare.org410-443-1360
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
oncology.clinical.trials@marshfieldresearch.org906-774-1313
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
314-996-5569
clinicaltrials@lakeregional.com573-302-2768
314-996-5569
417-269-4520
Danielle.Werle@mercy.net314-525-6042
314-996-5569
314-996-5569
314-996-5569
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
WCICTOresearch@urmc.rochester.edu
516-734-8896
212-434-4460
516-734-8896
585-758-7877
585-341-8113
ctsucontact@westat.com888-823-5923
585-275-5830
WCICTOresearch@urmc.rochester.edu
Jeffh@columbusccop.org614-488-2745
Jeffh@columbusccop.org614-488-2745
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
HemonCCTrials@geisinger.edu570-271-5251
HemonCCTrials@geisinger.edu570-374-8555
HemonCCTrials@geisinger.edu570-271-5251
rhonda.ballew@anmedhealth.org864-512-4651
underberga@sjchs.org912-819-5704
kmertz-rivera@gibbscc.org864-560-6104
Kim.Williams3@prismahealth.org864-522-4317
Kim.Williams3@prismahealth.org864-522-4317
Kim.Williams3@prismahealth.org864-522-4317
kmertz-rivera@gibbscc.org864-560-6104
underberga@sjchs.org912-819-5704
kmertz-rivera@gibbscc.org864-560-6104
kmertz-rivera@gibbscc.org864-560-6104
nemer.elmouallem@vcuhealth.org
William.Houck@usoncology.com540-662-1108
360-788-8223
kmakin-bond@peacehealth.org360-514-2016
research@valleymed.org425-228-3440
kmakin-bond@peacehealth.org360-514-3940
ResearchDept@thedacare.org920-364-3604
AWRI.inquiry@ascension.org
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
AWRI.inquiry@ascension.org
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
WI_research_admin@hshs.org920-433-8889
wi_research_admin@hshs.org920-433-8889
ncorp@aurora.org414-302-2304
ncorp@aah.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581
mmcorc@healthpartners.com952-993-1517
AWRI.inquiry@ascension.org
ncorp@aurora.org414-302-2304
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581
wi_research_admin@hshs.org920-433-8889
ncorp@aurora.org414-302-2304
AWRI.Inquiry@Ascension.org
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
oncology.clinical.trials@marshfieldresearch.org800-782-8581